经皮耳迷走神经刺激治疗帕金森病的作用及机制研究

注册号:

Registration number:

ITMCTR2025001470

最近更新日期:

Date of Last Refreshed on:

2025-07-21

注册时间:

Date of Registration:

2025-07-21

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

经皮耳迷走神经刺激治疗帕金森病的作用及机制研究

Public title:

Research on the Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in the Treatment of Parkinson's Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于微生物-肠-脑轴探讨经皮耳迷走神经刺激治疗帕金森病的作用及机制

Scientific title:

Based on the microbiota–gut–brain axis exploring the role and mechanism of transcutaneous auricular vagus nerve stimulation in the treatment of Parkinson's disease

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

傅成伟

研究负责人:

李哲

Applicant:

Chengwei Fu

Study leader:

Zhe Li

申请注册联系人电话:

Applicant telephone:

18064108739

研究负责人电话:

Study leader's telephone:

18064108739

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

405417101@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhel@gzucm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市白云区机场路12号

研究负责人通讯地址:

广东省广州市荔湾区芳村花地涌岸街36号

Applicant address:

12 Jichang Road Baiyun District Guangzhou Guangdong China

Study leader's address:

No. 36 Huadiyong'an Street Fangcun Liwan District Guangzhou Guangdong Province China

申请注册联系人邮政编码:

Applicant postcode:

510405

研究负责人邮政编码:

Study leader's postcode:

510120

申请人所在单位:

广州中医药大学第二临床医学院

Applicant's institution:

The Second Clinical College of Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BF2021-018-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021/2/19 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

XiaoYan Li

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Dade Road Yuexiu District Guangzhou Guangdong China

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-81887233-35943

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@gzucm.edu.cn

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市荔湾区芳村花地涌岸街36号

Primary sponsor's address:

No. 36 Huadiyong'an Street Fangcun Liwan District Guangzhou Guangdong Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院

具体地址:

广东省广州市荔湾区芳村花地涌岸街36号

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Address:

No. 36 Huadiyong'an Street Fangcun Liwan District Guangzhou Guangdong Province China

经费或物资来源:

国家自然科学基金委员会

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

帕金森病

研究疾病代码:

Target disease:

Parkinson's disease

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

揭示taVNS 对PD的疗效及作用机制,为PD治疗提供新方法,为taVNS 的PD临床应用提供理论依据

Objectives of Study:

This study aims to reveal the efficacy and mechanisms of taVNS in Parkinson's disease offering a new therapeutic strategy and theoretical support for its clinical application

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1、PD诊断符合《2015帕金森病的诊断标准》,无头部震颤;2、Hoehn-Yahr分级标准在Ⅰ~Ⅲ级之间;3、年龄在35~80岁之间;4、患者自愿参与本研究并签署知情同意书。

Inclusion criteria

1.Diagnosis of Parkinson's disease (PD) meets the "2015 MDS Diagnostic Criteria for Parkinson's Disease" without head tremor. 2.Hoehn and Yahr stage is between I and III. 3. Age between 35 and 80 years. 4.The patient voluntarily agrees to participate in this study and has signed the informed consent form.

排除标准:

1、PD患者为继发性帕金森综合征或帕金森叠加综合征患者;2、有严重的心、肝、肾、造血系统疾患或恶性肿瘤,有其他神经系统疾患、精神障碍,曾有脑外伤或行脑部手术者;3、各种原因不能行fMRI检查者。

Exclusion criteria:

1.Patients diagnosed with secondary parkinsonism or Parkinson-plus syndromes. 2.Patients with severe diseases of the heart liver kidneys or hematopoietic system or with malignant tumors; those with other neurological disorders psychiatric conditions a history of traumatic brain injury or previous brain surgery. 3.Patients who are unable to undergo fMRI examination for any reason.

研究实施时间:

Study execute time:

From 2021-02-28

To      2024-02-19

征募观察对象时间:

Recruiting time:

From 2021-05-01

To      2023-12-01

干预措施:

Interventions:

组别:

试验组

样本量:

39

Group:

Experimental Group

Sample size:

干预措施:

经皮耳迷走神经刺激组

干预措施代码:

Intervention:

Transcutaneous Auricular Vagus Nerve Stimulation Group

Intervention code:

组别:

对照组

样本量:

39

Group:

Control Group

Sample size:

干预措施:

耳舟非迷走神经刺激组

干预措施代码:

Intervention:

Auricular Non-Vagus Nerve Stimulation Group

Intervention code:

样本总量 Total sample size : 78

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院

单位级别:

三甲

Institution/hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

便秘生活质量自评量表

指标类型:

次要指标

Outcome:

Patient Assessment of Constipation – Quality of Life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

帕金森病自主神经功能障碍评估量表

指标类型:

次要指标

Outcome:

Scales for Outcomes in Parkinson’s Disease – Autonomic

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能磁共振

指标类型:

次要指标

Outcome:

fMRI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

次要指标

Outcome:

Hamilton Depression Rating Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

次要指标

Outcome:

Hamilton Anxiety Rating Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

便秘症状自评量表

指标类型:

次要指标

Outcome:

Patient Assessment of Constipation – Symptoms

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

帕金森病统一评分量表

指标类型:

主要指标

Outcome:

Movement Disothe Unified Parkinsons Disease Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

结束

Completed

年龄范围:

最小 35
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

委托临床研究方法学重点研究室用SPSS24.0生成随机数字表,把早中期PD患者随机分成taVNS 组、非taVNS 组,每组39例。

Randomization Procedure (please state who generates the random number sequence and by what method):

The Clinical Research Methodology Key Laboratory was entrusted to generate a random number table using SPSS 24.0 based on which early- to mid-stage Parkinsons disease (PD) patients were randomly assigned into a taVNS group and a non-taVNS group with 38 patients in each group.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1)研究者根据受试者的原始观察记录,保证将数据正确、完整、清晰、及时地载入病例报告表; 2)所有受试者资料全部从病例报告表录入EDC数据库; 3)数据库锁定; 4)数据导出、统计分析:统计分析使用SPSS或R; 5)数据备份、保存; ①研究者保存所有研究资料,包括对所有受试者的医院原始记录、所有原始的有签名的知情同意书,治疗的详细记录等;②病例报告表在按要求完成数据录入和核查后,按编号的顺序归档保存,并填有检索目录等,以备考察;③电子数据文件包括数据库、检查程序、分析程序、分析结果、编码本和说明文件等,应分类保存,并有多个备份保存于不同磁盘或记录介质上,妥善保存,防止损坏。所有原始文档按相应规定保存5年。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1) The investigator ensures that the data are correctly completely legibly and timely loaded onto the case report form based on the subject's original observation record. 2) All subject data were entered into the EDC database from the case report form. 3) Database locking. 4) Data export and statistical analysis using SPSS or R. 5) Data backup and preservation: (1) The investigator is responsible for saving all study data including the original hospital records of all subjects all original signed informed consent forms detailed records of treatment etc. (2) Once the case report form has been completed and verified it should be filed in the order of the number to save and fill in the search directory etc. In order to prepare for the examination the electronic data files including databases examination procedures analytical procedures analytical results codebooks and descriptions of the documents should be classified and saved. Furthermore multiple backups should be saved on different disks or recording media in order to prevent damage. In accordance with the pertinent regulations all original documents are to be retained for a period of five years.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统